Outcomes Similar for Neoadjuvant ICI-Based Therapy, Upfront Surgery for Liver Cancer
By Elana Gotkine HealthDay Reporter
THURSDAY, Aug. 22, 2024 -- Patients treated with neoadjuvant immune checkpoint inhibitor (ICI)-based therapy for hepatocellular carcinoma (HCC) have higher-risk disease features but achieve outcomes comparable to those undergoing upfront surgery, according to a study published online Aug. 15 in Cancer Research Communications.
Mari Nakazawa, M.D., from the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, and colleagues retrospectively examined the outcomes of patients who underwent surgical resection for HCC and compared clinical outcomes for patients who received neoadjuvant immunotherapy versus those who underwent upfront resection. A total of 92 patients were included; 36 received neoadjuvant ICI-based treatment.
The researchers found that 61.1 percent of the patients who received neoadjuvant ICI-based therapy were outside of standard resectability criteria and were more likely to have features linked to risk for disease recurrence. The rates of margin-negative resection and recurrence-free survival (RFS) were similar for patients who received neoadjuvant immunotherapy and those who underwent upfront surgical resection (median RFS, 44.8 versus 49.3 months). For patients with a pathologic response, a nonsignificant trend toward superior RFS was seen with neoadjuvant therapy.
"Our observations highlight the need for future prospective trials to further define the role of neoadjuvant ICI therapy in both traditionally resectable and high-risk localized HCC populations," the authors write.
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
THURSDAY, June 5, 2025 -- For patients with resectable gastric or gastroesophageal junction adenocarcinoma, durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel...
Endolymphatic Sac Decompression Effective for Vertigo, Migraine
WEDNESDAY, May 28, 2025 -- For Meniere disease (MD) patients with migraine, endolymphatic sac decompression (ELSD) is effective, providing postoperative relief of vertigo and...
One-Week Radiotherapy for Breast Cancer Safe, Effective Up to 10 Years
TUESDAY, May 27, 2025 -- A five-fraction, one-week schedule of adjuvant breast radiotherapy is as safe and effective as a standard three-week schedule for patients with invasive...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.